Материалы доступны только для специалистов сферы здравоохранения.
Чтобы посмотреть материал полностью
Авторизуйтесь
или зарегистрируйтесь.
Двойная антитромбоцитарная терапия как долгосрочное вмешательство в рамках вторичной профилактики после инфаркта миокарда: фокус на тикагрелор
Двойная антитромбоцитарная терапия как долгосрочное вмешательство в рамках вторичной профилактики после инфаркта миокарда: фокус на тикагрелор
Аверков О.В. Двойная антитромбоцитарная терапия как долгосрочное вмешательство в рамках вторичной профилактики после инфаркта миокарда: фокус на тикагрелор. Consilium Medicum. 2015; 17 (5): 38–43.
________________________________________________
Материалы доступны только для специалистов сферы здравоохранения.
Чтобы посмотреть материал полностью
Авторизуйтесь
или зарегистрируйтесь.
Аннотация
В аналитической статье представлено современное состояние антитромбоцитарной профилактики у больных, перенесших инфаркт миокарда.
За краткой исторической справкой следует подробное изложение замысла и результатов исследования PEGASUS-TIMI 54 (Prevention of Cardiovascular Events in Patients with Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin-Thrombolysis in Myocardial Infarction 54). По результатам этого исследования блокатор P2Y12-рецепторов тромбоцитов тикагрелор претендует на основное место в длительной двойной антитромбоцитарной терапии у пациентов, перенесших инфаркт миокарда. Окончательное решение о возможности использования тикагрелора по новому для него показанию – за разрешающими организациями и экспертными сообществами. Основания для выхода в клиническую практику есть у дозы тикагрелора 60 мг 2 раза в день.
Ключевые слова: тикагрелор, инфаркт миокарда, антитромбоцитарные средства, вторичная профилактика.
Key words: ticagrelor, myocardial infarction, antiplatelet drug, secondary prevention.
За краткой исторической справкой следует подробное изложение замысла и результатов исследования PEGASUS-TIMI 54 (Prevention of Cardiovascular Events in Patients with Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin-Thrombolysis in Myocardial Infarction 54). По результатам этого исследования блокатор P2Y12-рецепторов тромбоцитов тикагрелор претендует на основное место в длительной двойной антитромбоцитарной терапии у пациентов, перенесших инфаркт миокарда. Окончательное решение о возможности использования тикагрелора по новому для него показанию – за разрешающими организациями и экспертными сообществами. Основания для выхода в клиническую практику есть у дозы тикагрелора 60 мг 2 раза в день.
Ключевые слова: тикагрелор, инфаркт миокарда, антитромбоцитарные средства, вторичная профилактика.
________________________________________________
Key words: ticagrelor, myocardial infarction, antiplatelet drug, secondary prevention.
Полный текст
Список литературы
1. Sabatine MS, Cannon CP, Gibson CM et al. Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevation. N Engl J Med 2005; 352: 1179–89.
2. Chen ZM, Jiang LX, Chen YP et al. Addition of clopidogrel to aspirin in 45,852 patients with acute myocardial infarction: randomised placebo-controlled trial. Lancet 2005; 366: 1607–21.
3. Wiviott SD, Braunwald E, McCabe CH et al. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2007; 357: 2001–15.
4. Wallentin L, Becker RC, Budaj A et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2009; 361. Doi: 10.1056/NEJMoa0904327.
5. Steg G, James DK, Atar D et al. Acute Myocardial Infarction in patients presenting with ST-segment elevation (Management of). Eur Heart J 2012; 33: 2569–619.
6. O’Gara PT, Kushner FG, Ascheim DD et al. 2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation 2013: published online before print December 17, 2012, 10.1161/CIR.0b013e3182742c84.
7. Hamm CW, Bassand JP, Agewall S et al. ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: The Task Force for the management of acute coronary syndromes (ACS) in patients presenting without persistent ST-segment elevation of the European Society of Cardiology (ESC). Eur Heart J 2011; 32: 2999–3054.
8. Amsterdam EA, Wenger NK, Brindis RG et al. 2014 AHA/ACC guideline for the management of patients with non-ST-elevation acute coronary syndromes: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation 2014; 130 (25): 2354–94.
9. Fox KA, Anderson FA Jr, Goodman SG et al. Time course of events in acute coronary syndromes: implications for clinical practice from the GRACE registry. Nat Clin Pract Cardiovasc Med 2008; 5 (9): 580–9.
10. Rapsomaniki E, Thuresson M, Yang E et al. International comparison of outcomes among 140880 patients stable after acute MI; real world evidence from electronic health and administrative records. Presented at European Society of Cardiology Congress, Barcelona, Spain; 30 August – 3 September 2014.
11. Hallas J, Dall M, Andries A et al. Use of single and combined antithrombotic therapy and risk of serious upper gastrointestinal bleeding: population based case-control study. BMJ 2006; 333: 726–30.
12. Delaney JA, Opatrny L, Brophy JM, Suissa S. Drug-drug interactions between antithrombotic medications and the risk of gastrointestinal bleeding. CMAJ 2007; 177: 347–51.
13. Bonaca MP, Bhatt DL, Cohen M et al. Long-term use of ticagrelor in patients with prior myocardial infarction. N Engl J Med 2015; Doi: 10156/NEJMoa1500857.
14. Bhatt DL, Fox KA, Hacke W et al. Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events. N Engl J Med2006; 354: 1706–17.
15. Bhatt DL, Flather MD, Hacke W et al. Patients with prior myocardial infarction, stroke, or symptomatic peripheral arterial disease in the CHARISMA trial. J Am Coll Cardiol 2007; 49: 1982–8.
16. Morrow DA, Braunwald E, Bonaca MP et al. TRA 2P–TIMI 50 Steering Committee and, Investigators (Apr 12, 2012). Vorapaxar in the secondary prevention of atherothrombotic events. N Engl J Med 2012; 366 (15): 1404–13.
17. Scirica BM, Bonaca MP, Braunwald E et al. Vorapaxar for secondary prevention of thrombotic events for patients with previous myocardial infarction: a prespecified subgroup analysis of the TRA 2 P-TIMI 50 trial. Lancet 2012; 380: 1317–24.
2. Chen ZM, Jiang LX, Chen YP et al. Addition of clopidogrel to aspirin in 45,852 patients with acute myocardial infarction: randomised placebo-controlled trial. Lancet 2005; 366: 1607–21.
3. Wiviott SD, Braunwald E, McCabe CH et al. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2007; 357: 2001–15.
4. Wallentin L, Becker RC, Budaj A et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2009; 361. Doi: 10.1056/NEJMoa0904327.
5. Steg G, James DK, Atar D et al. Acute Myocardial Infarction in patients presenting with ST-segment elevation (Management of). Eur Heart J 2012; 33: 2569–619.
6. O’Gara PT, Kushner FG, Ascheim DD et al. 2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation 2013: published online before print December 17, 2012, 10.1161/CIR.0b013e3182742c84.
7. Hamm CW, Bassand JP, Agewall S et al. ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: The Task Force for the management of acute coronary syndromes (ACS) in patients presenting without persistent ST-segment elevation of the European Society of Cardiology (ESC). Eur Heart J 2011; 32: 2999–3054.
8. Amsterdam EA, Wenger NK, Brindis RG et al. 2014 AHA/ACC guideline for the management of patients with non-ST-elevation acute coronary syndromes: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation 2014; 130 (25): 2354–94.
9. Fox KA, Anderson FA Jr, Goodman SG et al. Time course of events in acute coronary syndromes: implications for clinical practice from the GRACE registry. Nat Clin Pract Cardiovasc Med 2008; 5 (9): 580–9.
10. Rapsomaniki E, Thuresson M, Yang E et al. International comparison of outcomes among 140880 patients stable after acute MI; real world evidence from electronic health and administrative records. Presented at European Society of Cardiology Congress, Barcelona, Spain; 30 August – 3 September 2014.
11. Hallas J, Dall M, Andries A et al. Use of single and combined antithrombotic therapy and risk of serious upper gastrointestinal bleeding: population based case-control study. BMJ 2006; 333: 726–30.
12. Delaney JA, Opatrny L, Brophy JM, Suissa S. Drug-drug interactions between antithrombotic medications and the risk of gastrointestinal bleeding. CMAJ 2007; 177: 347–51.
13. Bonaca MP, Bhatt DL, Cohen M et al. Long-term use of ticagrelor in patients with prior myocardial infarction. N Engl J Med 2015; Doi: 10156/NEJMoa1500857.
14. Bhatt DL, Fox KA, Hacke W et al. Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events. N Engl J Med2006; 354: 1706–17.
15. Bhatt DL, Flather MD, Hacke W et al. Patients with prior myocardial infarction, stroke, or symptomatic peripheral arterial disease in the CHARISMA trial. J Am Coll Cardiol 2007; 49: 1982–8.
16. Morrow DA, Braunwald E, Bonaca MP et al. TRA 2P–TIMI 50 Steering Committee and, Investigators (Apr 12, 2012). Vorapaxar in the secondary prevention of atherothrombotic events. N Engl J Med 2012; 366 (15): 1404–13.
17. Scirica BM, Bonaca MP, Braunwald E et al. Vorapaxar for secondary prevention of thrombotic events for patients with previous myocardial infarction: a prespecified subgroup analysis of the TRA 2 P-TIMI 50 trial. Lancet 2012; 380: 1317–24.
2. Chen ZM, Jiang LX, Chen YP et al. Addition of clopidogrel to aspirin in 45,852 patients with acute myocardial infarction: randomised placebo-controlled trial. Lancet 2005; 366: 1607–21.
3. Wiviott SD, Braunwald E, McCabe CH et al. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2007; 357: 2001–15.
4. Wallentin L, Becker RC, Budaj A et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2009; 361. Doi: 10.1056/NEJMoa0904327.
5. Steg G, James DK, Atar D et al. Acute Myocardial Infarction in patients presenting with ST-segment elevation (Management of). Eur Heart J 2012; 33: 2569–619.
6. O’Gara PT, Kushner FG, Ascheim DD et al. 2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation 2013: published online before print December 17, 2012, 10.1161/CIR.0b013e3182742c84.
7. Hamm CW, Bassand JP, Agewall S et al. ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: The Task Force for the management of acute coronary syndromes (ACS) in patients presenting without persistent ST-segment elevation of the European Society of Cardiology (ESC). Eur Heart J 2011; 32: 2999–3054.
8. Amsterdam EA, Wenger NK, Brindis RG et al. 2014 AHA/ACC guideline for the management of patients with non-ST-elevation acute coronary syndromes: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation 2014; 130 (25): 2354–94.
9. Fox KA, Anderson FA Jr, Goodman SG et al. Time course of events in acute coronary syndromes: implications for clinical practice from the GRACE registry. Nat Clin Pract Cardiovasc Med 2008; 5 (9): 580–9.
10. Rapsomaniki E, Thuresson M, Yang E et al. International comparison of outcomes among 140880 patients stable after acute MI; real world evidence from electronic health and administrative records. Presented at European Society of Cardiology Congress, Barcelona, Spain; 30 August – 3 September 2014.
11. Hallas J, Dall M, Andries A et al. Use of single and combined antithrombotic therapy and risk of serious upper gastrointestinal bleeding: population based case-control study. BMJ 2006; 333: 726–30.
12. Delaney JA, Opatrny L, Brophy JM, Suissa S. Drug-drug interactions between antithrombotic medications and the risk of gastrointestinal bleeding. CMAJ 2007; 177: 347–51.
13. Bonaca MP, Bhatt DL, Cohen M et al. Long-term use of ticagrelor in patients with prior myocardial infarction. N Engl J Med 2015; Doi: 10156/NEJMoa1500857.
14. Bhatt DL, Fox KA, Hacke W et al. Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events. N Engl J Med2006; 354: 1706–17.
15. Bhatt DL, Flather MD, Hacke W et al. Patients with prior myocardial infarction, stroke, or symptomatic peripheral arterial disease in the CHARISMA trial. J Am Coll Cardiol 2007; 49: 1982–8.
16. Morrow DA, Braunwald E, Bonaca MP et al. TRA 2P–TIMI 50 Steering Committee and, Investigators (Apr 12, 2012). Vorapaxar in the secondary prevention of atherothrombotic events. N Engl J Med 2012; 366 (15): 1404–13.
17. Scirica BM, Bonaca MP, Braunwald E et al. Vorapaxar for secondary prevention of thrombotic events for patients with previous myocardial infarction: a prespecified subgroup analysis of the TRA 2 P-TIMI 50 trial. Lancet 2012; 380: 1317–24.
________________________________________________
2. Chen ZM, Jiang LX, Chen YP et al. Addition of clopidogrel to aspirin in 45,852 patients with acute myocardial infarction: randomised placebo-controlled trial. Lancet 2005; 366: 1607–21.
3. Wiviott SD, Braunwald E, McCabe CH et al. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2007; 357: 2001–15.
4. Wallentin L, Becker RC, Budaj A et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2009; 361. Doi: 10.1056/NEJMoa0904327.
5. Steg G, James DK, Atar D et al. Acute Myocardial Infarction in patients presenting with ST-segment elevation (Management of). Eur Heart J 2012; 33: 2569–619.
6. O’Gara PT, Kushner FG, Ascheim DD et al. 2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation 2013: published online before print December 17, 2012, 10.1161/CIR.0b013e3182742c84.
7. Hamm CW, Bassand JP, Agewall S et al. ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: The Task Force for the management of acute coronary syndromes (ACS) in patients presenting without persistent ST-segment elevation of the European Society of Cardiology (ESC). Eur Heart J 2011; 32: 2999–3054.
8. Amsterdam EA, Wenger NK, Brindis RG et al. 2014 AHA/ACC guideline for the management of patients with non-ST-elevation acute coronary syndromes: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation 2014; 130 (25): 2354–94.
9. Fox KA, Anderson FA Jr, Goodman SG et al. Time course of events in acute coronary syndromes: implications for clinical practice from the GRACE registry. Nat Clin Pract Cardiovasc Med 2008; 5 (9): 580–9.
10. Rapsomaniki E, Thuresson M, Yang E et al. International comparison of outcomes among 140880 patients stable after acute MI; real world evidence from electronic health and administrative records. Presented at European Society of Cardiology Congress, Barcelona, Spain; 30 August – 3 September 2014.
11. Hallas J, Dall M, Andries A et al. Use of single and combined antithrombotic therapy and risk of serious upper gastrointestinal bleeding: population based case-control study. BMJ 2006; 333: 726–30.
12. Delaney JA, Opatrny L, Brophy JM, Suissa S. Drug-drug interactions between antithrombotic medications and the risk of gastrointestinal bleeding. CMAJ 2007; 177: 347–51.
13. Bonaca MP, Bhatt DL, Cohen M et al. Long-term use of ticagrelor in patients with prior myocardial infarction. N Engl J Med 2015; Doi: 10156/NEJMoa1500857.
14. Bhatt DL, Fox KA, Hacke W et al. Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events. N Engl J Med2006; 354: 1706–17.
15. Bhatt DL, Flather MD, Hacke W et al. Patients with prior myocardial infarction, stroke, or symptomatic peripheral arterial disease in the CHARISMA trial. J Am Coll Cardiol 2007; 49: 1982–8.
16. Morrow DA, Braunwald E, Bonaca MP et al. TRA 2P–TIMI 50 Steering Committee and, Investigators (Apr 12, 2012). Vorapaxar in the secondary prevention of atherothrombotic events. N Engl J Med 2012; 366 (15): 1404–13.
17. Scirica BM, Bonaca MP, Braunwald E et al. Vorapaxar for secondary prevention of thrombotic events for patients with previous myocardial infarction: a prespecified subgroup analysis of the TRA 2 P-TIMI 50 trial. Lancet 2012; 380: 1317–24.
Авторы
О.В.Аверков
ФГАОУ ВО Российский университет дружбы народов. 117198, Россия, Москва, ул. Миклухо-Маклая, д. 6;
ГБУЗ Городская клиническая больница №15 им. О.М.Филатова Департамента здравоохранения г. Москвы. 111539, Россия, Москва, ул. Вешняковская, д. 23
oleg.averkov@gmail.com
People’s Friendship University of Russia. 117198, Russian Federation, Moscow, ul. Miklukho-Maklaia, d. 6;
O.M.Filatov City clinical hospital №15 of the Department of Health of Moscow. 111539, Russian Federation, Moscow, ul. Veshniakovskaia, d. 23
oleg.averkov@gmail.com
ФГАОУ ВО Российский университет дружбы народов. 117198, Россия, Москва, ул. Миклухо-Маклая, д. 6;
ГБУЗ Городская клиническая больница №15 им. О.М.Филатова Департамента здравоохранения г. Москвы. 111539, Россия, Москва, ул. Вешняковская, д. 23
oleg.averkov@gmail.com
________________________________________________
People’s Friendship University of Russia. 117198, Russian Federation, Moscow, ul. Miklukho-Maklaia, d. 6;
O.M.Filatov City clinical hospital №15 of the Department of Health of Moscow. 111539, Russian Federation, Moscow, ul. Veshniakovskaia, d. 23
oleg.averkov@gmail.com
Цель портала OmniDoctor – предоставление профессиональной информации врачам, провизорам и фармацевтам.